Answers are grounded in this paper and cite their sources.
Cycloserine is a WHO group B drug for the treatment of multidrug-resistant tuberculosis (TB). Pharmacokinetic/pharmacodynamic data for cycloserine when dosed as terizidone are sparse. The aim of this analysis was to describe the population pharmacokinetics of cycloserine when administered as terizidone and predict the doses of terizidone attaining cycloserine exposures associated with efficacy. The plasma cycloserine level was measured 2 to 6 weeks after treatment initiation in patients hospitalized for second-line tuberculosis treatment.
No takes yet. Share an insight, caveat, or question.
Chirehwa et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: